Abstract PS6-11: TargetableERBB2mutation status is an independent marker of adverse prognosis in estrogen receptor positive,ERBB2non-amplified primary lobular breast carcinoma: Validation using a novel gene signature of HER2 activation
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs20-ps6-11
Abstract: Invasive lobular carcinoma (ILC) accounts for 10-15% of primary breast cancer and is typically ER+ and ERBB2 non-amplified. There is preclinical evidence that somatic ERBB2 mutation may provide an alternative and tractable mechanism for upregulation… read more here.
Keywords: novel gene; signature her2; carcinoma; signature ... See more keywords